Volume 1, Issue 2 (Summer-Fall 2017)                   Mod Med Lab J 2017, 1(2): 50-59 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sajjadi N, Mirnejad R, Sharif M, Piranfar V, Zaeifi D. Relevant Allelic Frequency of Gene Polymorphism and Genetic Predisposition of Human Papillomavirus in Patients with Cervical Cancer. Mod Med Lab J. 2017; 1 (2) :50-59
URL: http://modernmedlab.com/article-1-48-en.html
Abstract:   (8097 Views)

Backround: The present study investigated the correlation between p53 gene codon 72 polymorphism and 6 other genetic single nucleotide polymorphisms (SNPs) in patients with cervical cancer infected by HPV.

Methods: 450 patients with cervical cancer (280 Squamous cell carcinoma and 170 Adenocarcinoma) were followed at hospitals in Iran from Dec. 2014 to Apr. 2015. Moreover, 100 age/sex-matched were used as the control group. HPV was detected by LINEAR ARRAY® HPV Genotyping Test. Allelic frequency of 6 gene polymorphisms was detected by the amplification-refractory mutation system (ARMS).

Results: From 450 patients, 408 cases (90.66%) were positive for HPV. Four genotypes were observed as single infections (16, 18, 31, and 45). The most common genotypes were HPV-16 (73.52%), HPV-18 (23.28%), HPV-31 and 45 (3.17%), respectively. 306 samples were arginine-arginine homozygous (70.6% and 71.4% of adenocarcinoma and squamous cell carcinoma, respectively), 70 cases were arginine-proline heterozygous (17.6% of adenocarcinoma and 23.8% of squamous cell carcinoma), and 20 cases were as proline-proline homozygous (11.8% and 4.8% of adenocarcinoma and squamous cell carcinoma, respectively).

Conclusion: The prevalence of HPV was 84% and that was the estimation of the Global Burden among Iranian patients with cervical cancer (85% - 99%). There was no correlation between mutations in the p53 allele and the size/type of tumors, while we found a correlation between mutations in p53 alleles and age. Therefore, XRCC1 G399A SNP and TP53 G72C SNP were significantly correlated with the cervical cancer.


HPV: Human papillomavirus; SNP: Single nucleotide polymorphism; CDKN1A: cycling-dependent kinase inhibitor 1A; TP53: Tumor protein p53 (also known as p53); P53c72: p53 gene codon 72; ATM: Ataxia-telangiectasia mutated; HDM2: Human double minutes 2 (also known as MDM2); LIG4: DNA ligase IV; XRCC1: X-ray repair cross-complementing 1; XRCC3: X-ray repair cross-complementing 3; TGFB1: Transforming Growth Factor Beta 1; HWE’: Hardy-Weinberg equilibrium; FIGO stage: International Federation of Gynecology and Obstetrics tumor stage; 

Full-Text [PDF 440 kb]   (1193 Downloads)    
Type of Study: Original | Subject: Laboratory Methods

1. Kaarthigeyan K. Cervical cancer in India and HPV vaccination. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology. 2012;33(1):7-12. [DOI:10.4103/0971-5851.96961] [PMID] [PMCID]
2. Palefsky JM. Human papillomavirus-related disease in men: not just a women's issue. The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 2010;46(4 Suppl):S12-9.
3. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, et al. Human papillomavirus and HPV vaccines: a review. Bulletin of the World Health Organization. 2007;85(9):719-26. [DOI:10.2471/BLT.06.038414] [PMID] [PMCID]
4. Reitano M. Counseling patients with genital warts. The American journal of medicine. 1997;102(5A):38-43. [DOI:10.1016/S0002-9343(97)00182-4]
5. Turazza E, Lapena A, Sprovieri O, Torres CP, Gurucharri C, Maciel A, et al. Low-risk human papillomavirus types 6 and 11 associated with carcinomas of the genital and upper aero-digestive tract. Acta obstetricia et gynecologica Scandinavica. 1997;76(3):271-6. [PMID]
6. Palefsky JM, Holly EA, Ralston ML, Arthur SP, Hogeboom CJ, Darragh TM. Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease. Genitourinary medicine. 1997;73(3):174-80. [DOI:10.1136/sti.73.3.174]
7. Anic GM, Giuliano AR. Genital HPV infection and related lesions in men. Preventive medicine. 2011;53 Suppl 1:S36-41. [DOI:10.1016/j.ypmed.2011.08.002] [PMID] [PMCID]
8. Sugase M, Matsukura T. Distinct manifestations of human papillomaviruses in the vagina. International journal of cancer Journal international du cancer. 1997;72(3):412-5. https://doi.org/10.1002/(SICI)1097-0215(19970729)72:3<412::AID-IJC7>3.0.CO;2-S [DOI:10.1002/(SICI)1097-0215(19970729)72:33.0.CO;2-S]
9. Adams V, Moll C, Schmid M, Rodrigues C, Moos R, Briner J. Detection and typing of human papillomavirus in biopsy and cytological specimens by polymerase chain reaction and restriction enzyme analysis: a method suitable for semiautomation. Journal of medical virology. 1996;48(2):161-70. https://doi.org/10.1002/(SICI)1096-9071(199602)48:2<161::AID-JMV8>3.0.CO;2-7 [DOI:10.1002/(SICI)1096-9071(199602)48:23.0.CO;2-7]
10. Konno R, Paez C, Sato S, Yajima A, Fukao A. HPV, histologic grade and age. Risk factors for the progression of cervical intraepithelial neoplasia. The Journal of reproductive medicine. 1998;43(7):561-6. [PMID]
11. Nour NM. Cervical cancer: a preventable death. Reviews in obstetrics & gynecology. 2009;2(4):240-4. [PMID] [PMCID]
12. Graham SV. Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. Future microbiology. 2010;5(10):1493-506. [DOI:10.2217/fmb.10.107] [PMID] [PMCID]
13. Pierce Campbell CM, Messina JL, Stoler MH, Jukic DM, Tommasino M, Gheit T, et al. Cutaneous human papillomavirus types detected on the surface of male external genital lesions: a case series within the HPV Infection in Men Study. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2013;58(4):652-9. [DOI:10.1016/j.jcv.2013.10.011] [PMID] [PMCID]
14. Sundstrom K, Eloranta S, Sparen P, Arnheim Dahlstrom L, Gunnell A, Lindgren A, et al. Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19(10):2469-78. [DOI:10.1158/1055-9965.EPI-10-0424] [PMID] [PMCID]
15. Senchenko VN, Kisseljova NP, Ivanova TA, Dmitriev AA, Krasnov GS, Kudryavtseva AV, et al. Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer. Epigenetics. 2013;8(4):409-20. [DOI:10.4161/epi.24233] [PMID] [PMCID]
16. Yang WT, Zheng PS. Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis. PloS one. 2014;9(2):e88827. [DOI:10.1371/journal.pone.0088827] [PMID] [PMCID]
17. Alsbeih G, Al-Harbi N, El-Sebaie M, Al-Badawi I. HPV prevalence and genetic predisposition to cervical cancer in Saudi Arabia. Infectious agents and cancer. 2013;8(1):15. [DOI:10.1186/1750-9378-8-15] [PMID] [PMCID]
18. Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer research and treatment : official journal of Korean Cancer Association. 2005;37(6):319-24. [DOI:10.4143/crt.2005.37.6.319] [PMID] [PMCID]
19. Zedan W, Mourad MI, El-Aziz SM, Salamaa NM, Shalaby AA. Cytogenetic significance of chromosome 17 aberrations and P53 gene mutations as prognostic markers in oral squamous cell carcinoma. Diagnostic pathology. 2015;10:2. [DOI:10.1186/s13000-015-0232-1] [PMID] [PMCID]
20. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 0000;25(11):1602-11. [DOI:10.1038/sj.onc.1209367] [PMID]
21. Makni H, Franco EL, Kaiano J, Villa LL, Labrecque S, Dudley R, et al. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. International journal of cancer Journal international du cancer. 2000;87(4):528-33. https://doi.org/10.1002/1097-0215(20000815)87:4<528::AID-IJC11>3.0.CO;2-O [DOI:10.1002/1097-0215(20000815)87:43.0.CO;2-O]
22. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393(6682):229-34. [DOI:10.1038/30400] [PMID]
23. Neamatzadeh H, Soleimanizad R, Zare-Shehneh M, Gharibi S, Shekari A, Rahimzadeh AB. Association between p53 codon 72 (Arg72Pro) polymorphism and primary open-angle glaucoma in Iranian patients. Iranian biomedical journal. 2015;19(1):51-6. [PMID] [PMCID]
24. Yilmaz E, Celik O, Celik E, Turkcuoglu I, Simsek Y, Karaer A, et al. XPD and XRCC1 gene polymorphism in patients with normal and abnormal cervical cytology by pap smear. Eur Rev Med Pharmacol Sci. 2012;16(12):1713-8. [PMID]
25. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharmaceutical research. 2008;25(9):2097-116. [DOI:10.1007/s11095-008-9661-9] [PMID] [PMCID]
26. Alsbeih G, Ahmed R, Al-Harbi N, Venturina LA, Tulbah A, Balaraj K. Prevalence and genotypes' distribution of human papillomavirus in invasive cervical cancer in Saudi Arabia. Gynecologic oncology. 2011;121(3):522-6. [DOI:10.1016/j.ygyno.2011.01.033] [PMID]
27. Sina M, Pedram M, Ghojazadeh M, Kochaki A, Aghbali A. P53 gene codon 72 polymorphism in patients with oral squamous cell carcinoma in the population of northern Iran. Med Oral Patol Oral Cir Bucal. 2014;19(6):e550-5. [DOI:10.4317/medoral.19794] [PMID] [PMCID]
28. Alsbeih G, El-Sebaie M, Al-Rajhi N, Al-Harbi N, Al-Hadyan K, Al-Qahtani S, et al. Among 45 variants in 11 genes, HDM2 promoter polymorphisms emerge as new candidate biomarker associated with radiation toxicity. 3 Biotech. 2014;4(2):137-48. [DOI:10.1007/s13205-013-0135-3] [PMID] [PMCID]
29. Al-Hadyan KS, Al-Harbi NM, Al-Qahtani SS, Alsbeih GA. Involvement of single-nucleotide polymorphisms in predisposition to head and neck cancer in Saudi Arabia. Genetic testing and molecular biomarkers. 2012;16(2):95-101. [DOI:10.1089/gtmb.2011.0126] [PMID] [PMCID]
30. Watson RA. Human Papillomavirus: Confronting the Epidemic-A Urologist's Perspective. Reviews in urology. 2005;7(3):135-44. [PMID] [PMCID]
31. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecologic oncology. 2010;117(2 Suppl):S5-10. [DOI:10.1016/j.ygyno.2010.01.024] [PMID]
32. Dickson EL, Vogel RI, Luo X, Downs LS. Recent trends in type-specific HPV infection rates in the United States. Epidemiology and infection. 2015;143(5):1042-7. [DOI:10.1017/S0950268814001538] [PMID] [PMCID]
33. Khorasanizadeh F, Hassanloo J, Khaksar N, Mohammad Taheri S, Marzaban M, B HR, et al. Epidemiology of cervical cancer and human papilloma virus infection among Iranian women - analyses of national data and systematic review of the literature. Gynecologic oncology. 2013;128(2):277-81. [DOI:10.1016/j.ygyno.2012.11.032] [PMID]
34. Ghaffari SR, Sabokbar T, Mollahajian H, Dastan J, Ramezanzadeh F, Ensani F, et al. Prevalence of human papillomavirus genotypes in women with normal and abnormal cervical cytology in Iran. Asian Pacific journal of cancer prevention : APJCP. 2006;7(4):529-32. [PMID]
35. Jalilvand S, Shoja Z, Nourijelyani K, Tohidi HR, Hamkar R. Meta-analysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: Implications for screening and vaccination. Journal of medical virology. 2015;87(2):287-95. [DOI:10.1002/jmv.24053] [PMID]
36. Burd EM. Human papillomavirus and cervical cancer. Clinical microbiology reviews. 2003;16(1):1-17. [DOI:10.1128/CMR.16.1.1-17.2003] [PMID] [PMCID]
37. Coutlee F, Rouleau D, Ferenczy A, Franco E. The laboratory diagnosis of genital human papillomavirus infections. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale / AMMI Canada. 2005;16(2):83-91. [DOI:10.1155/2005/798710]
38. Ciotti M, Coletti A, Giuliani L, Cappiello G, Syrjanen K, Favalli C. The p53 codon 72 arg/arg homozygous women in central Italy are at increased risk for HPV infections. Anticancer research. 2006;26(5B):3745-8. [PMID]
39. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The Lancet Oncology. 2010;11(11):1048-56. [DOI:10.1016/S1470-2045(10)70230-8]
40. Seoud M. Burden of human papillomavirus-related cervical disease in the extended middle East and north Africa-a comprehensive literature review. Journal of lower genital tract disease. 2012;16(2):106-20. [DOI:10.1097/LGT.0b013e31823a0108] [PMID]
41. Shahsiah R, Khademalhosseini M, Mehrdad N, Ramezani F, Nadji SA. Human papillomavirus genotypes in Iranian patients with cervical cancer. Pathology, research and practice. 2011;207(12):754-7. [DOI:10.1016/j.prp.2011.09.011] [PMID]
42. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. European journal of cancer. 2009;45(15):2632-9. [DOI:10.1016/j.ejca.2009.07.019] [PMID]
43. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International journal of cancer Journal international du cancer. 2007;121(3):621-32. [DOI:10.1002/ijc.22527] [PMID]
44. Parlak M, Guducuoglu H, Bayram Y, Cikman A, Aypak C, Kilic S, et al. Identification and determination of antibiotic susceptibilities of Brucella strains isolated from patients in van, Turkey by conventional and molecular methods. International journal of medical sciences. 2013;10(10):1406-11. [DOI:10.7150/ijms.6565] [PMID] [PMCID]
45. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, et al. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia. 2004;6(5):529-35. [DOI:10.1593/neo.04178] [PMID] [PMCID]
46. Farshbaf-Khalili A, Salehi-Pourmehr H, Shahnazi M, Yaghoubi S, Gahremani-Nasab P. Cervical cancer screening in women referred to healthcare centres in Tabriz, Iran. Nigerian medical journal : journal of the Nigeria Medical Association. 2015;56(1):28-34. [DOI:10.4103/0300-1652.149167] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2021 CC BY-NC 4.0 | Modern Medical Laboratory Journal